Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:17:07.943Z.
Consensus retrieved: 2026-10-06T12:44:06.533Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:17:07.943Z.
Quote observation: 2026-10-06T14:15:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Forward PE Ratio (N/A) = Dated Quote Price ($3.99) / Consensus Forward EPS ($-1.12)
FORWARD PE RATIO
N/A
Immuneering Corporation
Market Cap
$144.85M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Immuneering Corporation (IMRX) | $144.85M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.22M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $142.72M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.84M | N/A |
| Alpha Cognition Inc (ACOG)vs › | $141.33M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $138.62M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $138.28M | 6.89 |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.12 | $-1.21 – $-1.06 | 6 | n/m |
| 2027-12-31 | $-1.26 | $-1.37 – $-1.09 | 6 | n/m |
| 2028-12-31 | $-1.13 | $-1.52 – $-0.98 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
